Published in J Am Soc Nephrol on November 19, 2014
The emerging role of coagulation proteases in kidney disease. Nat Rev Nephrol (2015) 0.76
Interplay between transglutaminases and heparan sulphate in progressive renal scarring. Sci Rep (2016) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem (1998) 5.99
Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int (2006) 4.87
The plasminogen activator/plasmin system. J Clin Invest (1991) 4.20
Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest (1985) 2.99
Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis (2008) 2.85
Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet (1968) 2.58
Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol (2006) 2.48
Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest (1996) 2.42
PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int (2001) 2.41
Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost (2001) 2.24
Expression of connective tissue growth factor in human renal fibrosis. Kidney Int (1998) 2.19
Structural-functional correlations in renal disease. II. The correlations. Hum Pathol (1970) 2.18
Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest (2002) 2.15
Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int (2005) 1.74
Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int (1994) 1.70
Endogenous urokinase lacks antifibrotic activity during progressive renal injury. Am J Physiol Renal Physiol (2007) 1.68
Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem (1995) 1.68
Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int (1993) 1.35
Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int (1997) 1.35
Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol (2003) 1.31
Interferon-gamma inhibits experimental renal fibrosis. Kidney Int (1999) 1.30
Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study. PLoS One (2011) 1.26
Thrombin and fibrinolysis. Chest (2003) 1.24
The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis. J Clin Invest (1997) 1.21
Tissue transglutaminase and the progression of human renal scarring. J Am Soc Nephrol (2003) 1.14
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest (2002) 1.13
Loss of TIMP3 enhances interstitial nephritis and fibrosis. J Am Soc Nephrol (2009) 1.10
Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: a potential target for preventing renal fibrosis. Am J Kidney Dis (2001) 1.07
The consequences of tubulo-interstitial changes for renal function in glomerulopathies. A morphometric and cytological analysis. Pathol Res Pract (1990) 1.06
Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney Int (2000) 0.99
Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. Invest Radiol (2010) 0.97
Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int (2001) 0.94
Matrix metalloproteinases and their inhibitions in experimental renal scarring. Exp Nephrol (2002) 0.93
Performance of novel kidney biomarkers in preclinical toxicity studies. Toxicol Sci (2010) 0.93
t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney Int (2001) 0.90
Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis. J Med Chem (2007) 0.90
Interstitial fibrosis in obstructive nephropathy. Kidney Int (1993) 0.89
Fibrinogen excretion in the urine and immunoreactivity in the kidney serves as a translational biomarker for acute kidney injury. Am J Pathol (2012) 0.88
Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease. J Thromb Thrombolysis (2013) 0.88
Development of a chronic kidney disease model in C57BL/6 mice with relevance to human pathology. Nephron Extra (2013) 0.88
Application of antibody array technology in the analysis of urinary cytokine profiles in patients with chronic kidney disease. Am J Nephrol (2006) 0.87
Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. Eur Heart J (2012) 0.86
Loss of TIMP3 selectively exacerbates diabetic nephropathy. Am J Physiol Renal Physiol (2012) 0.86
Glomerular basement membrane expansion in passive Heymann nephritis. Absence of increased synthesis of type IV collagen, laminin, or fibronectin. Am J Pathol (1991) 0.85
Progression of chronic renal disease in humans is associated with the deposition of basement membrane components and decorin in the interstitial extracellular matrix. Clin Nephrol (1995) 0.85
The effect of chronic kidney disease on fibrin clot properties in patients with acute coronary syndrome. Blood Coagul Fibrinolysis (2010) 0.85
A pilot trial assessing urinary gene expression profiling with an mRNA array for diabetic nephropathy. PLoS One (2012) 0.85
Heterozygosity for fibrinogen results in efficient resolution of kidney ischemia reperfusion injury. PLoS One (2012) 0.84
Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury. Kidney Int (1994) 0.84
Protective role of thrombin activatable fibrinolysis inhibitor in obstructive nephropathy-associated tubulointerstitial fibrosis. J Thromb Haemost (2007) 0.80
An inhibitor of thrombin activated fibrinolysis inhibitor (TAFI) can reduce extracellular matrix accumulation in an in vitro model of glucose induced ECM expansion. Matrix Biol (2013) 0.79
Role of fibrinogen in acute ischemic kidney injury. Am J Physiol Renal Physiol (2013) 0.79
Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int (1999) 0.78
Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency. Thromb Haemost (2008) 0.78
Plasminogen activator inhibitor-1 is associated with renal dysfunction independent of BMI and serum lipid levels in patients with type 2 diabetes. Diabetes Res Clin Pract (2012) 0.76